Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT02339922

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

A Window Study of Ixazomib in Untreated Indolent B-NHL

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
33 (actual)
Sponsor
University of Washington · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well ixazomib citrate and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that grows slowly (indolent). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving ixazomib citrate together with rituximab may work better in treating indolent B-cell non-Hodgkin lymphoma.

Detailed description

OUTLINE: Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days and then every 3 months for 3 years.

Conditions

Interventions

TypeNameDescription
DRUGIxazomib CitrateGiven PO
OTHERLaboratory Biomarker AnalysisCorrelative studies
BIOLOGICALRituximabGiven IV

Timeline

Start date
2016-05-19
Primary completion
2024-12-30
Completion
2031-01-06
First posted
2015-01-16
Last updated
2026-03-05
Results posted
2026-03-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02339922. Inclusion in this directory is not an endorsement.